Literature DB >> 9863710

Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion.

O Salomon1, J Moisseiev, N Rosenberg, O Vidne, I Yassur, A Zivelin, G Treister, D M Steinberg, U Seligsohn.   

Abstract

The purpose of this study was to investigate the role of genetic polymorphisms associated with venous and arterial thrombosis in patients with retinal vein occlusion (RVO). One-hundred and two consecutive patients with RVO were examined for factor V G1691A and factor II G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T and apolipoprotein E4 by amplification of specific DNA fragments and restriction analysis. The risks exerted by these polymorphisms and by the conventional risk factors of RVO were evaluated by comparing their frequencies among patients and controls and by estimating the respective odds ratios. We found that the prevalences of the factor V G1691A, factor II G20210A, and apolipoprotein E4 polymorphisms were similar in the study and control groups. Logistic regression analysis involving the parameters for which significant differences were detected disclosed an odds ratio of 1.9 for MTHFR C677T homozygosity (95% confidence interval 0.95-3.81), an odds ratio of 2.12 for hypertension (95% confidence interval 1.16-3.73) and an odds ratio of 3.25 for a family history of stroke (95% confidence interval 1.07-9.51). Our data suggests that homozygosity for the MTHFR C677T polymorphism is a risk factor of RVO in addition to arterial hypertension and a family history of stroke.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863710     DOI: 10.1097/00001721-199810000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.

Authors:  C Hvarfner; A Hillarp; J Larsson
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

2.  Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion.

Authors:  S Boyd; D Owens; T Gin; K Bunce; H Sherafat; D Perry; P G Hykin
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

Review 3.  Retinal vein occlusions: a review for the internist.

Authors:  Rossella Marcucci; Francesco Sofi; Elisa Grifoni; Andrea Sodi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2010-12-14       Impact factor: 3.397

4.  Methylenetetrahydrofolate reductase C677T mutation and risk of retinal vein thrombosis.

Authors:  Mohammad Soleiman Soltanpour; Zahra Soheili; Ali Shakerizadeh; Ali Akbar Pourfathollah; Shahram Samiei; Reza Meshkani; Mohammad Shahjahani; Abbas Karimi
Journal:  J Res Med Sci       Date:  2013-06       Impact factor: 1.852

Review 5.  Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis.

Authors:  Dan Li; Minwen Zhou; Xiaoyan Peng; Huiyu Sun
Journal:  BMC Ophthalmol       Date:  2014-11-27       Impact factor: 2.209

6.  Factor V G1691A is associated with an increased risk of retinal vein occlusion: a meta-analysis.

Authors:  Yuanyuan Zou; Xi Zhang; Jingyi Zhang; Xiangning Ji; Yuqing Liu
Journal:  Oncotarget       Date:  2017-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.